Danish Medicines Council could be a roadblock for sclerosis drug Kesimpta
Kesimpta has not blown the council away, a draft assessment of the Genmab-developed drug’s clinical value suggests.
by mikkel aabenhus hemmingsen, translated by catherine brett
Although sclerosis drug Kesimpta has been on somewhat of a worldwide victory tour, and generated sales of almost DKK 1.5bn (USD 230m) in the first three quarters of this year, the Danish Medicines Council is not convinced of its advantages.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: Novartis's Kesimpta sales exceeded expectations
For subscribers
Novartis beats expectations for third quarter
For subscribers
Leo Pharma strongly criticizes Danish Medicines Council
For subscribers
.jpg&w=384&q=75)
